Cargando…

Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia

Patient: Female, 67-year-old Final Diagnosis: Enoxaparin induced thrombocytopenia with life threatening thrombosis Symptoms: Chest discomfort Medication:— Clinical Procedure: — Specialty: Hematology OBJECTIVE: Educational purpose BACKGROUND: Heparin, often used as an anticoagulant, acts by binding t...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Navdeep, Lubana, Sandeep Singh, Tsai, Han-mou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286187/
https://www.ncbi.nlm.nih.gov/pubmed/32469847
http://dx.doi.org/10.12659/AJCR.922498
_version_ 1783544831251841024
author Singh, Navdeep
Lubana, Sandeep Singh
Tsai, Han-mou
author_facet Singh, Navdeep
Lubana, Sandeep Singh
Tsai, Han-mou
author_sort Singh, Navdeep
collection PubMed
description Patient: Female, 67-year-old Final Diagnosis: Enoxaparin induced thrombocytopenia with life threatening thrombosis Symptoms: Chest discomfort Medication:— Clinical Procedure: — Specialty: Hematology OBJECTIVE: Educational purpose BACKGROUND: Heparin, often used as an anticoagulant, acts by binding to antithrombin III. Indeed, heparin binds to a variety of proteins other than antithrombin III. Among them, platelet factor 4 can bind and neutralize the anticoagulant activity of heparin. Upon binding with heparin, platelet factor 4 undergoes a conformational change and expresses immunogenic neo-epitopes that induce the generation of antibodies of the platelet factor 4 heparin complex. This immune reaction may lead to thrombocytopenia and venous, arterial, or microvascular thrombosis. However, the risk of such complications is quite variable, as it is affected not only by the source and dose of heparin and the clinical condition (e.g., cardiovascular surgery and orthopedic surgery) of the patient, but also the molecular size of the heparin formulation. Venous, arterial, and small-vessel thrombosis can lead to leg swelling, pulmonary embolism, stroke, skin necrosis, or gangrene requiring limb amputation or intestinal resection. Myocardial infarction due to coronary thrombosis also occurs, although it is less common and can be readily recognized. CASE REPORT: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication of heparin therapy. We report the case of a 67-year-old woman who developed ST-segment elevation myocardial infarction and thrombocytopenia within 10 days of prophylactic enoxaparin therapy after undergoing bilateral total knee replacement surgery. She also had peripheral arterial and venous thrombosis. With thrombolysis and argatroban anticoagulation therapy, she recovered without residual sequelae. CONCLUSIONS: Thrombocytopenia with coronary and other vascular thrombosis is a potentially serious complication of heparin therapy. A trend of decreased platelet count, decreased platelet count by 30% or more, and/or occurrence of any type of thrombosis should raise the suspicion of HIT. This case demonstrates that early recognition and prompt treatment of HIT can be life-saving.
format Online
Article
Text
id pubmed-7286187
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-72861872020-06-19 Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia Singh, Navdeep Lubana, Sandeep Singh Tsai, Han-mou Am J Case Rep Articles Patient: Female, 67-year-old Final Diagnosis: Enoxaparin induced thrombocytopenia with life threatening thrombosis Symptoms: Chest discomfort Medication:— Clinical Procedure: — Specialty: Hematology OBJECTIVE: Educational purpose BACKGROUND: Heparin, often used as an anticoagulant, acts by binding to antithrombin III. Indeed, heparin binds to a variety of proteins other than antithrombin III. Among them, platelet factor 4 can bind and neutralize the anticoagulant activity of heparin. Upon binding with heparin, platelet factor 4 undergoes a conformational change and expresses immunogenic neo-epitopes that induce the generation of antibodies of the platelet factor 4 heparin complex. This immune reaction may lead to thrombocytopenia and venous, arterial, or microvascular thrombosis. However, the risk of such complications is quite variable, as it is affected not only by the source and dose of heparin and the clinical condition (e.g., cardiovascular surgery and orthopedic surgery) of the patient, but also the molecular size of the heparin formulation. Venous, arterial, and small-vessel thrombosis can lead to leg swelling, pulmonary embolism, stroke, skin necrosis, or gangrene requiring limb amputation or intestinal resection. Myocardial infarction due to coronary thrombosis also occurs, although it is less common and can be readily recognized. CASE REPORT: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication of heparin therapy. We report the case of a 67-year-old woman who developed ST-segment elevation myocardial infarction and thrombocytopenia within 10 days of prophylactic enoxaparin therapy after undergoing bilateral total knee replacement surgery. She also had peripheral arterial and venous thrombosis. With thrombolysis and argatroban anticoagulation therapy, she recovered without residual sequelae. CONCLUSIONS: Thrombocytopenia with coronary and other vascular thrombosis is a potentially serious complication of heparin therapy. A trend of decreased platelet count, decreased platelet count by 30% or more, and/or occurrence of any type of thrombosis should raise the suspicion of HIT. This case demonstrates that early recognition and prompt treatment of HIT can be life-saving. International Scientific Literature, Inc. 2020-05-29 /pmc/articles/PMC7286187/ /pubmed/32469847 http://dx.doi.org/10.12659/AJCR.922498 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Singh, Navdeep
Lubana, Sandeep Singh
Tsai, Han-mou
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia
title Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia
title_full Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia
title_fullStr Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia
title_full_unstemmed Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia
title_short Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia
title_sort myocardial infarction with limb arterial and venous thrombosis in a patient with enoxaparin-induced thrombocytopenia
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286187/
https://www.ncbi.nlm.nih.gov/pubmed/32469847
http://dx.doi.org/10.12659/AJCR.922498
work_keys_str_mv AT singhnavdeep myocardialinfarctionwithlimbarterialandvenousthrombosisinapatientwithenoxaparininducedthrombocytopenia
AT lubanasandeepsingh myocardialinfarctionwithlimbarterialandvenousthrombosisinapatientwithenoxaparininducedthrombocytopenia
AT tsaihanmou myocardialinfarctionwithlimbarterialandvenousthrombosisinapatientwithenoxaparininducedthrombocytopenia